BVF Partners L.P. entered into a Voting and Support Agreement with Ligand Pharmaceuticals Incorporated, agreeing to vote their shares in favor of the merger between XOMA and Ligand's subsidiary, Flex Merger Sub, Inc. They also agreed to convert their Series X Preferred Stock to common shares to facilitate voting and not to transfer their shares or assert appraisal rights.

Agreements · BVF Partners L.P. entered into a Voting and Support Agreement with Ligand Pharmaceuticals Incorporated, committing to vote their shares in favor of the merger and convert preferred stock to common shares for voting purposes. The agreement also includes provisions against transferring shares and waiving appraisal rights.

Agreements · The Issuer entered into a registration rights agreement with April 2026 PIPE Investors, including RA Capital, to register for resale the April 2026 PIPE Shares and April 2026 Warrant Shares. The Issuer agreed to file a registration statement within 45 days of the April 2026 Private Placement closing and use best efforts to keep it effective until all Registrable Securities are resold or can be resold under Rule 144 without volume or manner-of-sale limitations.

The Reporting Persons intend to review their investment in ImageneBio, Inc. based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or dispose of existing shares in the open market or privately negotiated transactions.

Agreements · Perceptive Credit Holdings III, L.P. entered into a senior secured financing arrangement with MeiraGTx Holdings plc, providing an initial $75 million term loan and an additional $25 million term loan tranche. In connection with this, MeiraGTx issued warrants exercisable for 700,000 Ordinary Shares, with the exercise price adjusted to $8.00 per share.

The Reporting Persons intend to review their investment in Prelude Therapeutics Inc. based on various factors and may acquire or dispose of shares in the future. They have not formulated any plans or proposals for extraordinary corporate transactions, changes to the board or management, or alterations to the company's capitalization or business structure.

Baker Brothers Advisors' entities, 667 and Life Sciences, purchased 114,601 and 2,137,651 Prefunded Warrants, respectively, in Prelude Therapeutics' public offering. The Prefunded Warrants were priced at $4.4399 per warrant, with an exercise price of $0.0001 per share, and were acquired using working capital.

Agreements · Dr. Scherer, a director, entered into a Lock-Up Agreement effective April 20, 2026, restricting him from selling or transferring any beneficially owned Common Stock or related securities until June 19, 2026, without the underwriters' consent. The filing also incorporates by reference the terms of the Prefunded Warrants purchased in the offering.

Agreements · RedCo II Master novated swap agreements to Special Purpose Vehicles (SPVs) on a pro-rata basis without consideration, maintaining the original terms and economic exposure.

The Reporting Persons intend to review their investment in Sionna Therapeutics Inc. based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire or dispose of shares or other securities of the Issuer in the open market or privately negotiated transactions, but have not formulated any plans for extraordinary corporate transactions, changes to the board or management, or material changes to the Issuer's capitalization or business structure.

Agreements · In connection with Spyre Therapeutics' public offering, Fairmount Funds Management LLC entered into a 60-day lock-up agreement, restricting the sale of company securities without underwriter consent. Fairmount Funds Management LLC did not participate in the offering.

The Issuer entered into an Implementation Agreement providing for a Scheme of Arrangement under Singapore law, where all ordinary shares of the Issuer will be exchanged on a one-for-one basis for newly issued shares of common stock of Wave-Delaware, and the Issuer will become a subsidiary of Wave-Delaware. This Redomiciliation is conditioned on shareholder approval and will result in stockholder rights being governed by Delaware law.

Felix J. Baker, Ph.D. was nominated to serve as a director and Lead Director of the Issuer until the 2027 annual general meeting. Michael Goller and Ranjeev Krishana, both employees of the Adviser, are not standing for re-election and their service is anticipated to expire on June 11, 2026.